Meeting Report

New Frontiers: The Role of CAR T-Cell Therapy in Multiple Myeloma

Alli McClanahan, APRN, and Megan Spychalla, PA-C

From Mayo Clinic, Rochester, Minnesota

Presenters’ disclosures of conflicts of interest are found at the end of this article.


J Adv Pract Oncol 2022;13(3):328–332 | https://doi.org/10.6004/jadpro.2022.13.3.30 | © 2022 Harborside™


  

ABSTRACT

Multiple myeloma remains the second most common hematologic malignancy, and relapse rates are high, with refractory disease common with each relapse. Chimeric antigen receptor (CAR)–modified T cells are a promising new treatment, and at JADPRO Live Virtual 2021, presenters compared pivotal trials in CAR T-cell therapy for multiple myeloma, discussed how to recognize and manage common toxicities after CAR T-cell infusion, and reviewed pre-CAR-T consultation and post-CAR-T management.




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.